Products
Calendar
Audience
Events
Contact
A new way to advertise on our platform
Products
Calendar
Audience
Events
Contact

Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

The state of consumer health

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss

BeOne kicks off ‘One Save Changes Everything’ campaign with Tim Howard

Design Therapeutics' Friedreich ataxia data; Vincentage's obesity results from China

Japan Brokerages Prepare for Crypto ETF Expansion

Drugmakers guard IP more tightly amid China competition

Polymarket seeks Japan market approval by 2030 for prediction markets

Ipsen details growing pains as teens transition to adult care

Atropos Health and Guidehouse Launch Point-of-Care Clinical Decision Support Solution for Life Sciences

Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA…

Doceree has bold ambitions to bring a new software category to pharma brand teams, one that reshapes campaign deployment in the…

Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule…

After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to…

On Thursday, the Health Tech team led a series of conversations at the Financial Times’ US Pharma and Biotech Summit, held in…

The FDA is looking to get thrifty with its approved drugs. | The framework would leverage existing safety data on approved drugs…